Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|September 6, 2019
Considerations for Clinical Translation of MG1 Maraba VirusCaroline J BreitbachEbiomedicine|July 14, 2016
Oncolytic Viruses: Therapeutics With an Identity CrisisCaroline J Breitbach, Brian D Lichty, John C BellCurrent Opinion in Virology|May 20, 2015
Oncolytic viruses: perspectives on clinical developmentJames Burke, Jorge Nieva, Mitesh J Borad, et al.Current Opinion in Molecular Therapeutics|January 30, 2008
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?Marianne M Stanford, Caroline J Breitbach, John C Bell, et al.Nature Reviews. Cancer|July 4, 2014
Going viral with cancer immunotherapyBrian D Lichty, Caroline J Breitbach, David F Stojdl, et al.Current Pharmaceutical Biotechnology|July 12, 2011
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594Caroline J Breitbach, Steve H Thorne, John C Bell, et al.Cytokine & Growth Factor Reviews|May 18, 2010
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approvalCaroline J Breitbach, Tony Reid, James Burke, et al.Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular CarcinomaCaroline J Breitbach, Anne Moon, James Burke, et al.Cytokine & Growth Factor Reviews|March 27, 2010
Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic virusesNaomi De Silva, Harold Atkins, David H Kirn, et al.Oncolytic Virotherapy|August 12, 2016
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)Caroline J Breitbach, John C Bell, Tae-Ho Hwang, et al.Pageof 4